We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

303 hedge funds and large institutions have $2.69B invested in Intellia Therapeutics in 2022 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 119 increasing their positions, 81 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more call options, than puts

Call options by funds: $22.8M | Put options by funds: $11.7M

47% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 81

2% more ownership

Funds ownership: 89.54% → 91.54% (+2%)

5% less funds holding

Funds holding: 319 → 303 (-16)

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

18% less first-time investments, than exits

New positions opened: 49 | Existing positions closed: 60

29% less capital invested

Capital invested by funds: $3.81B → $2.69B (-$1.11B)

Holders
303
Holders Change
-16
Holders Change %
-5.02%
% of All Funds
4.87%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.11%
New
49
Increased
119
Reduced
81
Closed
60
Calls
$22.8M
Puts
$11.7M
Net Calls
+$11.1M
Net Calls Change
+$803K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$67.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$56.7M
3
BlackRock
BlackRock
New York
+$53.6M
4
State Street
State Street
Massachusetts
+$50.7M
5
Morgan Stanley
Morgan Stanley
New York
+$47M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$19.3M
2
APM
Avidity Partners Management
Texas
-$17.2M
3
Goldman Sachs
Goldman Sachs
New York
-$16.9M
4
Millennium Management
Millennium Management
New York
-$13.3M
5
AIM
ARK Investment Management
Florida
-$11.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
76
Credit Suisse
Switzerland
$3.23M +$454K +9,549 +12%
CS
77
Candriam SCA
Luxembourg
$3.18M -$2.38M -50,000 -35%
Squarepoint
78
Squarepoint
New York
$3.18M +$4.03M +84,834 +1,349%
GC
79
Guggenheim Capital
Illinois
$3.02M +$712K +14,977 +21%
BNP Paribas Financial Markets
80
BNP Paribas Financial Markets
France
$2.82M -$1.59M -33,459 -29%
Fidelity International
81
Fidelity International
Bermuda
$2.8M +$3.81M +80,115 New
Russell Investments Group
82
Russell Investments Group
United Kingdom
$2.67M -$284K -5,969 -7%
Legal & General Group
83
Legal & General Group
United Kingdom
$2.53M +$185K +3,893 +6%
PM
84
Prosight Management
Texas
$2.52M +$3.43M +72,116 New
SAM
85
Sectoral Asset Management
Quebec, Canada
$2.49M – – –
Wells Fargo
86
Wells Fargo
California
$2.45M -$663K -13,938 -17%
State of Wisconsin Investment Board
87
State of Wisconsin Investment Board
Wisconsin
$2.39M +$14.1K +297 +0.4%
EWM
88
Elmwood Wealth Management
California
$2.37M – – –
GC
89
Gratus Capital
Georgia
$2.35M +$3.2M +67,311 New
JF
90
Jump Financial
Illinois
$2.34M +$2.8M +58,840 +705%
New York State Common Retirement Fund
91
New York State Common Retirement Fund
New York
$2.32M +$348K +7,320 +12%
Manulife (Manufacturers Life Insurance)
92
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.24M +$461K +9,696 +18%
Jane Street
93
Jane Street
New York
$2.13M +$1.43M +30,092 +97%
LOAMS
94
Lombard Odier Asset Management (Switzerland)
Switzerland
$2.13M – – –
Janus Henderson Group
95
Janus Henderson Group
United Kingdom
$1.89M +$1.39M +29,283 +118%
Millennium Management
96
Millennium Management
New York
$1.75M -$13.3M -280,321 -85%
RPAM
97
Rhenman & Partners Asset Management
Sweden
$1.74M – – –
TD Asset Management
98
TD Asset Management
Ontario, Canada
$1.73M +$199K +4,178 +9%
Lazard Asset Management
99
Lazard Asset Management
New York
$1.66M -$1.9M -39,889 -46%
State of New Jersey Common Pension Fund D
100
State of New Jersey Common Pension Fund D
New Jersey
$1.63M +$134K +2,814 +6%
2 3
4
5 6

NTLA Hedge Fund Activity: Q4 2022 in Review

303 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2022, worth a combined $2.69B — down 29% from $3.81B a quarter earlier.

Sellers outnumbered buyers: 60 funds closed out of NTLA and 49 opened new positions — a net loss of 11 holders — while 81 trimmed existing stakes and 119 added.

The largest buyer was Wellington Management Group, adding an estimated $67.5M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $19.3M sold.

  • 303 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2022, down from 319 in Q3 2022.
  • Funds reported $2.69B of Intellia Therapeutics stock for Q4 2022, down 29% quarter-over-quarter.
  • 49 funds opened new Intellia Therapeutics positions in Q4 2022 and 60 closed out, a net change of -11 holders.
  • The largest Intellia Therapeutics buyer in Q4 2022 was Wellington Management Group, an estimated $67.5M added.
  • The largest Intellia Therapeutics seller in Q4 2022 was PFM Health Sciences, an estimated $19.3M sold.

Based on aggregated 13F filings for Q4 2022.